IMODI, a French consortium
to develop new experimental models of cancer
Meet the needs of the scientific community in R&D of more efficient test systems
Cancer remains a progressive disease with high incidence, mortality and associated costs. The World Health Organization estimates that the cancer mortality will increase by more than 50% between 2002 and 2030, with about 11.5 million deaths in 2030 worldwide.
In this context, IMODI organizes a health industrial sector to meet the needs of the scientific community, whether private or public, in research and development of more efficient test systems to improve the selection of more effective diagnostic and therapeutic agents.
Scientific research is moving… Stay informed about our latest experimental models for the diagnosis and treatment in cancer.
IMODI (Innovative MODels Initiative) is a French consortium, involving both academic and private partners. It includes observational clinical studies in breast, ovary, pancreas, lungs, prostate, and liver cancers. By subscribing to our newsletter, you will receive the latest news from our partners and scientific advances about new experimental models of cancer.
REGISTER NOW
IMODI focuses its activities on 3 major R&D axes
Organization
SMEs
Big Pharmas
Academic Institutions
IMODI Products
- In vivo Models
- Ex vivo primoculture Models
- In vitro cell lines
- Biological material
- In silico Models
- Software
Tissue Microarray (from PDX)
Plasma (from patients or PDX) Soon available
Stools (from patients or PDX)
IMODI Services
- In vivo Pharmacology
- In vitro Assays
- Ex vivo Assays
- Data Mining
- Microbiota Analysis
- Biomedical Research
In vitro cytotoxicity on patients or PDX-derived cell lines
Identification of in silico predictive models
Identification of biomarkers
